On Oct. 7, 2020, Mateon Therapeutics announced the first patient enrolled this week in its Phase IV study ARTI-19. This is a global study with India to contribute at least 120 pts to the total aggregate of 3000 pts. The study evaluated the safety and efficacy of Artemisia absinthium Powder 500mg capsule (ArtiShieldTM ) in the treatment of adults with COVID-19. Top-line data from ARTI-19 was expected by end of 4Q20.